Zhejiang Jingxin`s Generic Colesevelam Hydrochloride Receives Approval In US
China`s generic drug makers struggle to survive bulk-buy policy onslaught
Mapi Pharma Ltd., a privately held, fully integrated, clinical stage biopharmaceutical company headquartered in Israel has completed an equity investment of $10 million by Zhejiang Jingxin Pharmaceutical Co., Ltd. a publicly listed Chinese pharmaceutical company manufacturing products for neurological, cardiovascular, and digestive system indications. Jingxin is also a current shareholder of Mapi Pharma, following an initial $10 million investment in 2016.
M&A this week: Oxis International, Hangzhou Tianmushan, Zhejiang Jingxin Pharmaceutical